🇺🇸 FDA
Patent

US 7763719

Variants of humanized anti-carcinoma MAb CC49

granted A61KA61K2039/505A61K38/00

Quick answer

US patent 7763719 (Variants of humanized anti-carcinoma MAb CC49) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Jul 22 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Jul 27 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 22 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K2039/505, A61K38/00, A61K49/0002, A61K51/1045